TargetMol

voxelotor

Product Code:
 
TAR-T7581
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7581-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7581-10mg10mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7581-25mg25mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7581-50mg50mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7581-100mg100mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7581-200mg200mg£511.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
voxelotor is an inhibitor of sickle hemoglobin (HbS)
CAS:
1446321-46-5
Formula:
C19H19N3O3
Molecular Weight:
337.379
Purity:
0.9994
SMILES:
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O

References

Shu P, You G, Li W, et al.Cefmetazole sodium as an allosteric effector that regulates the oxygen supply efficiency of adult hemoglobin.Journal of Biomolecular Structure and Dynamics.2023: 1-15. Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease[J]. Hematology Reports, 2018, 10(2). Hutchaleelaha A , Patel M , Washington C , et al. Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease[J]. British Journal of Clinical Pharmacology, 2019.